These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 8951189)
1. Pharmacokinetics and pharmacodynamics of (+/-)-sotalol in healthy male volunteers. Kimura M; Umemura K; Ikeda Y; Kosuge K; Mizuno A; Nakanomyo H; Ohashi K; Nakashima M Br J Clin Pharmacol; 1996 Nov; 42(5):583-8. PubMed ID: 8951189 [TBL] [Abstract][Full Text] [Related]
2. Prediction of sotalol-induced maximum steady-state QTc prolongation from single-dose administration in healthy volunteers. Le Coz F; Funck-Brentano C; Poirier JM; Kibleur Y; Mazoit FX; Jaillon P Clin Pharmacol Ther; 1992 Oct; 52(4):417-26. PubMed ID: 1424415 [TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacokinetic and pharmacodynamic properties of oral and intravenous (+)-sotalol in healthy volunteers. Uematsu T; Kanamaru M; Nakashima M J Pharm Pharmacol; 1994 Jul; 46(7):600-5. PubMed ID: 7996391 [TBL] [Abstract][Full Text] [Related]
4. Assessment of the effect of a single oral dose of telithromycin on sotalol-induced qt interval prolongation in healthy women. Démolis JL; Strabach S; Vacheron F; Funck-Brentano C Br J Clin Pharmacol; 2005 Aug; 60(2):120-7. PubMed ID: 16042664 [TBL] [Abstract][Full Text] [Related]
5. A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects. Salazar DE; Much DR; Nichola PS; Seibold JR; Shindler D; Slugg PH J Clin Pharmacol; 1997 Sep; 37(9):799-809. PubMed ID: 9549633 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects. Barbey JT; Sale ME; Woosley RL; Shi J; Melikian AP; Hinderling PH Clin Pharmacol Ther; 1999 Jul; 66(1):91-9. PubMed ID: 10430114 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia. Saul JP; Ross B; Schaffer MS; Beerman L; Melikian AP; Shi J; Williams J; Barbey JT; Jin J; Hinderling PH; Clin Pharmacol Ther; 2001 Mar; 69(3):145-57. PubMed ID: 11240979 [TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia. Shi J; Ludden TM; Melikian AP; Gastonguay MR; Hinderling PH J Pharmacokinet Pharmacodyn; 2001 Dec; 28(6):555-75. PubMed ID: 11999292 [TBL] [Abstract][Full Text] [Related]
9. Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modelling in a phase 1 study with oral rac-sotalol. Darpo B; Karnad DR; Badilini F; Florian J; Garnett CE; Kothari S; Panicker GK; Sarapa N Br J Clin Pharmacol; 2014 Mar; 77(3):522-31. PubMed ID: 23819796 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic profiles of d-sotalol and d,l-sotalol. Funck-Brentano C Eur Heart J; 1993 Nov; 14 Suppl H():30-5. PubMed ID: 7904936 [TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics of d-sotalol and d,l-sotalol in healthy volunteers. Poirier JM; Jaillon P; Lecocq B; Lecocq V; Ferry A; Cheymol G Eur J Clin Pharmacol; 1990; 38(6):579-82. PubMed ID: 2373132 [TBL] [Abstract][Full Text] [Related]
12. QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol. Somberg JC; Preston RA; Ranade V; Molnar J Cardiology; 2010; 116(3):219-25. PubMed ID: 20693799 [TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of sotalol. Hanyok JJ Am J Cardiol; 1993 Aug; 72(4):19A-26A. PubMed ID: 8346722 [TBL] [Abstract][Full Text] [Related]
14. [Plasma level and action of sotalol-HCL on the ECG interval after parenteral administration in healthy subjects]. Rehm KD; Schnelle K; Dyde CJ; Blümner E; Arendts W Arzneimittelforschung; 1987 Sep; 37(9):1058-62. PubMed ID: 3435602 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of intravenously and orally administered sotalol hydrochloride in horses and effects on surface electrocardiogram and left ventricular systolic function. Broux B; De Clercq D; Decloedt A; De Baere S; Devreese M; Van Der Vekens N; Ven S; Croubels S; van Loon G Vet J; 2016 Feb; 208():60-4. PubMed ID: 26670333 [TBL] [Abstract][Full Text] [Related]
16. Detection of QTc interval prolongation using jacket telemetry in conscious non-human primates: comparison with implanted telemetry. Derakhchan K; Chui RW; Stevens D; Gu W; Vargas HM Br J Pharmacol; 2014 Jan; 171(2):509-22. PubMed ID: 24372552 [TBL] [Abstract][Full Text] [Related]
17. Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. Läer S; Elshoff JP; Meibohm B; Weil J; Mir TS; Zhang W; Hulpke-Wette M J Am Coll Cardiol; 2005 Oct; 46(7):1322-30. PubMed ID: 16198851 [TBL] [Abstract][Full Text] [Related]
19. Tolerance to the repolarization effects of rac-sotalol during long-term treatment. Padrini R; Gusella M; Al Bunni M; Piovan D; Zordan R; Magnolfi G; Maiolino P; Ferrari M Br J Clin Pharmacol; 1997 Nov; 44(5):463-70. PubMed ID: 9384463 [TBL] [Abstract][Full Text] [Related]
20. Clinical Pharmacology-Driven Translational Research to Optimize Bedside Therapeutics of Sotalol Therapy. Dahmane E; Tang K; Gobburu JVS; Mattingly TJ; Reed BN; See VY; Ayres J; Ivaturi V Clin Transl Sci; 2019 Nov; 12(6):648-656. PubMed ID: 31328888 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]